Study on NESP for Treating Anaemia in Chemotherapy Patients
Author Information
Author(s): Glaspy J, Jadeja J Singh, Justice G, Kessler J, Richards D, Schwartzberg L, Rigas J, Kuter D, Harmon D, Prow D, Demetri G, Gordon D, Arseneau J, Saven A, Hynes H, Boccia R, O'Byrne J, Colowick A B
Primary Institution: UCLA School of Medicine
Hypothesis
Is NESP safe and effective for treating anaemia in patients undergoing chemotherapy?
Conclusion
NESP is well tolerated and shows a dose-response relationship in improving haemoglobin levels in chemotherapy patients.
Supporting Evidence
- NESP was administered once per week for up to 12 weeks.
- Patients were monitored for adverse events and effects on haemoglobin.
- No antibody formation to NESP was detected during the study.
- Mean change in haemoglobin at end of treatment was 1.24, 1.73, and 2.15 g dl−1 for the three dose cohorts.
Takeaway
This study tested a new medicine called NESP to help people with low blood levels while they are getting cancer treatment, and it worked well without causing problems.
Methodology
The study was a sequential, unblinded, and dose-escalating trial with three dose cohorts.
Potential Biases
Potential bias due to the unblinded nature of the study.
Limitations
The study was unblinded and had a limited follow-up period.
Participant Demographics
Patients with solid tumours receiving multicycle chemotherapy.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website